SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : SFCC provides outsourced drug development research services
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: SI Bob who wrote (19)1/27/2006 11:28:15 AM
From: Skywatcher   of 29
 
From FORBES
Losers? Drug tester SFBC International (nasdaq: SFCC - news - people ), which ranked 11th on our 2005 Fastest-Growing Technology list, fell 51% over the past 12 months.

SFBC stirred up controversy with some of its drug-testing practices, and, as a result, they are responding to an informal Securities and Exchange Commission inquiry along with a number of class-action suits from investors. SFBC has rejected the allegations based on the findings of its independent counsel review, which it forwarded to the Senate Finance Committee as requested by Sen. Charles Grassley. But the company recently changed top management.

Although SFBC’s $362 million in trailing-12 month revenue shows a 152% year-over-year increase, its current difficulties and strong drop in share price kept it off of this year’s Fast Tech list.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News